Download PDF
Thromb Haemost 1988; 60(02): 217-219
DOI: 10.1055/s-0038-1647032
Original Article
Schattauer GmbH Stuttgart

Relative Sensitivity of Different Tests in the Detection of Low Titer Lupus Anticoagulants

B Lesperance
The Hôpital Ste-Justine, Université de Montréal McGill University, Montreal, Canada
,
M David
The Hôpital Ste-Justine, Université de Montréal McGill University, Montreal, Canada
,
J Rauch
*   The Montreal General Research Institute, McGill University, Montreal, Canada
,
C Infante-Rivard
The Hôpital Ste-Justine, Université de Montréal McGill University, Montreal, Canada
,
G E Rivard
The Hôpital Ste-Justine, Université de Montréal McGill University, Montreal, Canada
› Author Affiliations
Further Information

Publication History

Received 30 March 1988

Accepted after revision 20 May 1988

Publication Date:
28 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Lupus anticoagulants (LA) and anticardiolipin antibodies have been strongly associated with recurrent abortion and fetal death. Because steroids have been reported to improve the fetal outcome of LA associated pregnancies, presumably by decreasing the levels of LA, it becomes desirable to have a simple and reliable test to monitor the levels of the putative antibody. To this effect, we assessed the capacity of the following coagulation tests to detect the presence of LA in serial dilutions of patient plasma with pooled normal plasma: kaolin clotting time (KCT), tissue thromboplastin inhibition test (TTIT), dilute Russell Viper venom time (DRVVT) and activated partial thromboplastin time with standard and high concentrations of phospholipids (SC and HCAPTT). All samples were also evaluated for the presence of anticardiolipin antibodies with an ELISA. The KCT was able to detect LA at a much greater dilution in normal plasma than any of the other clotting assays. The ELISA was comparable to KCT in its ability to detect high dilutions of LA.

Keywords

Lupus anticoagulant - Coagulation factor assays - Anticardiolipin antibodies - Thrombosis - Fetal loss
 

  • References

  • 1 Thiagarajan P, Shapiro SS, De MarcoL. Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity: mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
    CrossrefPubMedGoogle Scholar
  • 2 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb 1972; 1: 75-95
    PubMedGoogle Scholar
  • 3 Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622
    PubMedGoogle Scholar
  • 4 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 499-509
    PubMedGoogle Scholar
  • 5 Shapiro SS, Thiagarajan P. Lupus anticoagulant. Prog Hemostasis Thromb 1982; 6: 263-285
    PubMedGoogle Scholar
  • 6 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 1985; 15: 254-262
    PubMedGoogle Scholar
  • 7 Gordlund B. The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus. Acta Med Scand 1984; 215: 293-298
    PubMedGoogle Scholar
  • 8 Feinstein DI. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985; 313: 1348-1350
    CrossrefPubMedGoogle Scholar
  • 9 Lubbe WF, Liggins GC. Lupus anticoagulant and pregnancy. Am J Obstet Gynecol 1985; 153: 322-327
    CrossrefPubMedGoogle Scholar
  • 10 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Lupus anticoagulant in pregnancy. Br J Obstet Gynecol 1984; 91: 357-363
    CrossrefPubMedGoogle Scholar
  • 11 Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322-1326
    CrossrefPubMedGoogle Scholar
  • 12 Harris EN, Loizou S, Englert H, Derue G, Chan JK, Gharavi AE, Hughs GRV. Anticardiolipin antibodies and lupus anticoagulant. Lancet 1984; 2: 1099
    CrossrefPubMedGoogle Scholar
  • 13 Harris EN, Gharavi AE, Boly ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1213
    PubMedGoogle Scholar
  • 14 Loizou S, Mc Créa JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA); standardisation and quantitation of, results. Clin Exp Immunol 1985; 62: 738-745
    PubMedGoogle Scholar
  • 15 Lockshin M, Druzin ML, Goli S, Qamar T, Magig MS, Jovanovic L, Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-156
    CrossrefPubMedGoogle Scholar
  • 16 Hazeltine M, Rauch J, Danoff D, Esdaile JM, Tannenbaum H. Antiphospholipid antibodies in systemic lupus erythematosus: Evidence of an association with positive Coomb’s and hypocomplementenna. J Rheumatol 1988; 15: 80-86
    PubMedGoogle Scholar
  • 17 Green D, Hougie C, Kazmier FJ, Lechner K, Mannucci P, Rizza CR, Sultan Y. Report of the working party on acquired inhibitors of coagulation: studies of the “lupus” anticoagulant. Thromb Haemostas 1983; 49: 144-146
    PubMedGoogle Scholar
  • 18 Exner T, Richard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral pattern. Br J Haematol 1978; 40: 143-151
    CrossrefPubMedGoogle Scholar
  • 19 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venon time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
    PubMedGoogle Scholar
  • 20 Rosove MH, Ismail M, Koziol BJ, Runge A, Kasper CK. Lupus anticoagulants: Improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472-478
    PubMedGoogle Scholar
  • 21 Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibitor procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
    CrossrefPubMedGoogle Scholar
  • 22 Elashoff JD. Analysis of repeated measures designs, BMDP Tech Rep No. 83. 1986
    Google Scholar
  • 23 Fleiss JL. The Design and Analysis of Clinical Experiments. John Wiley & Sons; New York : 1986
    Google Scholar
  • 24 Makie IJ, Colaco CB, Machin SJ. Familial lupus anticoagulants. Br J Haematol 1987; 67: 359-363
    CrossrefPubMedGoogle Scholar
  • 25 Lockwood CJ, Reece EA, Romero R, Hobbins JC. Antiphospholipid antibody and pregnancy wastage. Lancet 1986; 2: 742-743
    PubMedGoogle Scholar
  • 26 Petri M, Rheinschmidt M, Whiting-O’Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time. Russell viper venom time and anticardiolipin antibody level. Ann Intern Med 1987; 106: 524-531
    CrossrefPubMedGoogle Scholar
  • 27 Lafer EM, Rauch J, Andrzejwski C, Mudd D, Furie B, Schwartz RS, Stollar D. Polyspecific monoclonal lupus antibodies reactive with both polynucleotides and phospholipids. J Exp Med 1981; 153: 897-909
    CrossrefPubMedGoogle Scholar
  • 28 Tannenbaum M, Rauch J, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid system. J Biol Chem 1986; 261: 9672-9677
    PubMedGoogle Scholar